CoreWeave (NASDAQ: CRWV) accelerates past $5bn revenue as AI infrastructure demand hardens into long-term contracts
CoreWeave, Inc.’s Q4 2025 results reveal explosive AI cloud growth, massive backlog expansion, and bold 2026 guidance. Discover what this means for investors.
Lilly’s Olumiant moves closer to European approval for teen alopecia patients as CHMP issues positive opinion
Eli Lilly's Olumiant wins CHMP backing for adolescent alopecia areata with 42% response rates — EU approval imminent, U.S. decision due late 2026. Read the full analysis.
EQT is out. What its €190m Azelis exit says about private equity timing in specialty chemicals
EQT has exited Azelis Group NV with a €190 million selldown. Find out what this means for investors, valuation, and the specialty chemicals sector.
Lifeway Foods (Nasdaq: LWAY) launches Muscle Mates and Kefir Butter at Expo West 2026 as brand marks 40-year milestone
Lifeway Foods (LWAY) debuts Muscle Mates and Kefir Butter at Expo West 2026. Here's what the dual launch signals for the cultured dairy sector. Read more.
Is Burnham Holdings finally done with legacy liabilities after Crown Boiler’s Chapter 11 filing?
Burnham Holdings, Inc. (OTC: BURCA) moves Crown Boiler into Chapter 11 to resolve legacy liabilities. Discover what this means for investors and the boiler sector.
Bill Clinton blasts Epstein committee for subpoenaing Hillary, denies any wrongdoing
Former President Bill Clinton testified before the House Oversight Committee on Feb. 27, 2026, in the first-ever congressional deposition of a former U.S. president.
Warner Bros. Discovery (WBD) shareholders to receive $31 per share as Paramount Skydance (PSKY) tables $110bn bid
Paramount Skydance to acquire Warner Bros. Discovery for $110B, merging HBO Max, Paramount+, and two major studios. What it means for streaming rivals and investors. Read more.
KEYNOTE-B96 final analysis: Merck’s Keytruda cuts death risk by 18% in recurrent ovarian cancer across all-comer population
Merck's Keytruda cuts death risk 18% in platinum-resistant ovarian cancer regardless of PD-L1 status. FDA approved, EU opinion positive. Read the full analysis.
NVIDIA (NASDAQ: NVDA) just doubled quarterly profit. The real test starts now
NVIDIA Corporation reported $215.9B fiscal 2026 revenue and $120B net income. Discover what this signals for AI infrastructure and investors.
Why Eni SpA’s 2025 earnings may matter more in 2027 than today
Eni SpA’s 2025 earnings reveal a shift toward balance sheet strength, disciplined growth, and lower risk. Find out what changes next.